Rubicon Research announced the acquisition of MeditabSpecialities’ oral liquid dosage and nasal product manufacturing facility located in Satara, Maharashtra. MeditabSpecialities is a wholly-owned subsidiary of Cipla.
A company statement informed, “The Satara facility is a state-of-the-art cGMP compliant and MHRA (UK) inspected production site that enables a strong and diverse pipeline of oral liquids for Rubicon Research. The company will seek additional regulatory approvals at the Satara site, including from the US FDA.”
“The acquisition of an outstanding oral liquid and nasal inhalers manufacturing facility advances our plan to offer a wider portfolio to our customers. These capabilities combined with our R&D expertise strengthens our ability to offer best-in-class drug products across dosage forms, which will benefit patients around the world. On behalf of Rubicon Research, I welcome our new colleagues and am confident that together we can continue to grow and make Rubicon Research one of the top 10 specialty generic pharmaceutical companies in the world,” said Parag Sancheti, Chief Executive Officer, Rubicon Research.